Study of STIM1 Membrane Expression

Recruiting

• Conditions: Autoimmune Diseases

• Registration Number: NCT04978948
• Lead Sponsor: University Hospital, Brest

Brief Summary

The aim of this study is to determine the expression of STIM1 in the plasma membrane of lymphocytes from patients suffering from different autoimmune diseases in order to identify new pathologies of interest presenting an over-expression of STIM1PM.

This would allow to initiate, following this study, research and development programs on the use of anti-STIM1 antibodies in these identified autoimmune diseases of interest.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-05-04
• Study Start: 2021-05-11
• Study First Submitted QC: 2021-07-25
• Study First Posted: 2021-07-27
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-04
• Last Update Posted: 2025-02-06
• Primary Completion: 2027-05
• Study Completion: 2027-05

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 670

Inclusion Criteria

• Diagnosis of one of the autoimmune diseases

Exclusion Criteria

• Treatment with rituximab in the previous 12 months

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
level of STIM1-PM	Day 0	Membrane expression level of STIM1-PM on the surface of immune cells, measured by flow cytometry

Secondary Outcome Measures

Name	Time	Method
correlation between STIM1 expression and Clinical Score	Day 0	Study of correlation between STIM1 expression on different cells and clinical scores of different autoimmune diseases or treatments received

Trial Locations

Locations (4)

Centre Hospitalier de Quimper; 🇫🇷 Quimper, Brittany, France

CHRU de Brest - Service de rhumatologie; 🇫🇷 Brest, France

CHU de Martinique; 🇫🇷 Fort-de-France, Martinique, France

Centre Hospitalier des Pays de Morlaix; 🇫🇷 Morlaix, Brittany, France